Advertisement

Could AstraZeneca and Sanofi Win Big in RSV?

AstraZeneca (NASDAQ: AZN) and its partner Sanofi (NASDAQ: SNY) recently announced promising results from a late-stage study of nirsevimab in preventing respiratory syncytial virus (RSV) in infants. In this Motley Fool Live video recorded on April 28, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the two companies can win big with this experimental RSV therapy.